We are live on ! Find out more
ASBP

Aspire Biopharma
ASBP

59 hedge funds and large institutions have $260M invested in Aspire Biopharma in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

175% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 4

13% more funds holding

Funds holding: 52 → 59 (+7)

8% more capital invested

Capital invested by funds: $241M → $260M (+$18.9M)

0% more ownership

Funds ownership: 0.07% → 0.07% (+0%)

22% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 9

Holders
59
Holders Change
+7
Holders Change %
+13.46%
% of All Funds
1.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
7
Reduced
9
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HCM
Highbridge Capital Management
New York
+$8.73M
2
Goldman Sachs
Goldman Sachs
New York
+$4.55M
3
MF
Magnetar Financial
Illinois
+$4M
4
SCM
Shaolin Capital Management
Florida
+$2.51M
5
PC
Periscope Capital
Ontario, Canada
+$2.29M

Top Sellers

Rank Fund Capital Flow
1
AA
AQR Arbitrage
Connecticut
-$4.56M
2
WAM
Wolverine Asset Management
Illinois
-$3.67M
3
HI
HBK Investments
Texas
-$2.99M
4
CCM
Context Capital Management
California
-$2.52M
5
Verition Fund Management
Verition Fund Management
Connecticut
-$2.02M
Name Holding Trade Value Shares
Change 		Change in
Stake
Nomura Holdings
26
Nomura Holdings
Japan
$3.04M – – –
WA
27
Whitebox Advisors
Minnesota
$2.54M – – –
SCM
28
Shaolin Capital Management
Florida
$2.54M +$2.51M +208 New
UOC
29
UBS O'Connor
Illinois
$2.33M -$241K -20 -9%
WAM
30
Weiss Asset Management
Massachusetts
$2.03M – – –
Hudson Bay Capital Management
31
Hudson Bay Capital Management
Connecticut
$2.03M – – –
KL
32
KIM LLC
Kansas
$2.03M – – –
WP
33
Woodline Partners
California
$2.03M – – –
PAMP
34
Polar Asset Management Partners
Ontario, Canada
$1.78M +$1.76M +146 New
PMAM
35
Picton Mahoney Asset Management
Ontario, Canada
$1.52M – – –
CCM
36
CAAS Capital Management
New York
$1.52M – – –
Parallax Volatility Advisers
37
Parallax Volatility Advisers
California
$1.44M +$1.42M +118 New
Citigroup
38
Citigroup
New York
$1.3M +$1.01M +84 +365%
AC
39
Aristeia Capital
Connecticut
$1.27M +$1.26M +104 New
CSS
40
Cubist Systematic Strategies
Connecticut
$1.24M – – –
CCM
41
Context Capital Management
California
$1.01M -$2.52M -209 -72%
OCM
42
Oaktree Capital Management
California
$1.01M – – –
ACM
43
Atalaya Capital Management
New York
$1.01M +$1M +83 New
KKRC
44
Kohlberg Kravis Roberts & Co
New York
$761K – – –
CH
45
CVI Holdings
Delaware
$507K – – –
MTCM
46
Mint Tower Capital Management
Netherlands
$507K – – –
UBS Group
47
UBS Group
Switzerland
$497K – – –
PCM
48
Prelude Capital Management
New York
$478K +$471K +39 New
DAM
49
DLD Asset Management
New York
$439K – – –
CM
50
Cohanzick Management
New York
$377K – – –
1
2
3

ASBP Hedge Fund Activity: Q3 2022 in Review

59 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma (ASBP) for Q3 2022, worth a combined $260M — up 7.8% from $241M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new ASBP positions and 4 closed out — a net gain of 7 holders — while 7 added to existing stakes and 9 trimmed.

The largest buyer was Highbridge Capital Management, adding an estimated $8.73M. The largest seller was AQR Arbitrage, cutting an estimated $4.56M.

  • 59 institutional investors held Aspire Biopharma (ASBP) as of Q3 2022, up from 52 in Q2 2022.
  • Funds reported $260M of Aspire Biopharma stock for Q3 2022, up 7.8% quarter-over-quarter.
  • 11 funds opened new Aspire Biopharma positions in Q3 2022 and 4 closed out, a net change of +7 holders.
  • The largest Aspire Biopharma buyer in Q3 2022 was Highbridge Capital Management, an estimated $8.73M added.
  • The largest Aspire Biopharma seller in Q3 2022 was AQR Arbitrage, an estimated $4.56M sold.

Based on aggregated 13F filings for Q3 2022.